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Background
Inflammation plays a pivotal role in the pathogenesis of coronary artery disease (CAD) (1) controlling not only the evolution of atheromatous plaque but also its propensity for rupture or erosion, by altering the matrix composition (2) . In addition, inflammation, through the activation and differentiation of the inflammatory cells involved, increases the thrombogenicity of the plaque's interior by promoting tissue factor bearing microparticle (MP) release with subsequent thrombus formation over the ruptured or eroded plaque (3) (4) (5) .
Patients with diseases associated with chronic inflammation such as diabetes mellitus, metabolic syndrome and chronic inflammatory autoimmune diseases are at increased risk of developing CAD (6) . In vivo inflammatory activity can be assessed by measuring C-reactive protein (CRP), serum amyloid antigen (SAA) tumour necrosis factor α (TNF-α) and
Interleukin-6 (IL-6). High levels of inflammatory markers in ACS patients were shown to be associated with adverse outcomes (7-10). However, whether or not increased levels of these inflammatory markers is merely an association or have any causal relationship with the pathogenesis of ACS remains to be established (9, 11, 12) . Furthermore, the source of inflammatory markers in ACS is still a matter of debate. It has also been shown that higher levels of IL-6 are found in the coronary artery when compared to the systemic arterial circulation in patients with ACS (13, 14) . While elevated inflammatory markers such as CRP and SAA, which are synthesised in the liver, indicate systemic inflammation, the above evidence supports the concept that intracoronary inflammation may also occur in close to proximity to the site of injury. This indicates that assessment of inflammatory markers in the peripheral circulation may not truly reflect the true burden of the intracoronary inflammatory process.
Emerging evidence indicates that MPs released from activated cells are potent pro-coagulant and pro-inflammatory molecules that may contribute to thrombus formation (3) and
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4 endothelial dysfunction (15) . It is possible that locally produced MPs may therefore contribute to the local coronary inflammatory processes in ACS (16) (17) (18) (19) , although the exact mechanisms are currently poorly understood. Several clinical studies have shown correlation between circulating MP levels and clinical outcomes, markers of myocardial damage, inflammation and indices of microvascular dysfunction (20) (21) (22) (23) (24) (25) .
The aim of this study was therefore to explore the relationship between coronary and systemic MP levels, circulating markers of inflammation, and extent of myocardial necrosis in patients with ACS. 
Methods
Study population
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Coronary angiography, PCI and blood sampling STEMI cohort was loaded with 300 mg of Aspirin and 600 mg of Clopidogrel prior to PCI.
NSTEMI patients received 300mg Aspirin followed by 75mg once daily (OD); 300mg
Clopidogrel followed by 75mg OD and low molecular weight heparin prior to PCI. SA patients were treated with aspirin 75mg OD and clopidogrel 75mg OD for at least 7 days prior to PCI.
Coronary angiography was carried out through trans femoral access. Right atrial blood samples were obtained using a 5F multipurpose catheter (5F, Cordis ®, internal diameter 0.11cm) via the femoral vein. Left and right coronary artery angiography was performed with a 5F Judkin's left 4 and right 4 diagnostic catheters (Cordis ®, internal diameter 0.11cm).
Following diagnostic angiography the culprit lesion was identified and weight adjusted unfractionated heparin was given prior to advancing the guide wire to achieve an activated clotting time (ACT) of 200 and 250 sec. After wiring of the culprit lesion an aspiration catheter (Medtronic ® Export catheter, internal diameter 0.10 cm) was advanced distal to the culprit lesion and 10 millilitres (mls) of blood was aspirated. Catheters with similar internal diameter were used for blood sample collection to minimise shear stress related in vitro platelet activation. PCI was performed according to standard procedures following blood sampling.
MP identification and characterization using flow cytometry
Blood was collected in 3.2% buffered citrate bottle and transferred immediately from cardiac catheterization laboratory to the haematology laboratory. The samples were centrifuged twice at 5,000 g for 5 minutes to obtain platelet-poor plasma (PPP) which was stored at -80o counts, the number of wells into which the plasma sample was divided (7 wells) and divided
by the exact volume of plasma (200μl) from which the microparticles were analysed, as described by Combes et al (28) .
Preparation of whole blood for platelet-monocyte aggregate (PMA) flow cytometry
PMA were identified as previously described (29 
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Measurement of plasma TNF-α, IL-6, hs-CRP, SAA and Troponin T
Plasma TNF-α and IL-6 levels were measured using a quantitive sandwich enzyme immunoassay technique as per manufacturer instructions (R&D systems, Europe). CRP was measured in plasma using a high sensitivity automated microparticle enhanced latex turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics GmbH). SAA was measured in plasma using latex nephelometry (BNII autoanalyser; Dade Behring, Marburg, Germany).
Troponin T was measured from plasma using the Elecsys troponin T high-sensitive assay (Roche Diagnostics).
Statistical analyses
Continuous variables were expressed as medians with interquartile range (IQR). Categorical variables were expressed as percentages with 95% confidence intervals. Comparisons between patient groups and coronary and right atrial compartments were performed using the Mann-Whitney U test. Fisher's exact test was used for comparison of proportions; and the Spearman rank correlation coefficient was used for correlations. Differences with a 2-sided p value <0.05 was considered to be statistically significant. All statistical analyses were performed with GraphPad Prism 5 statistical software.
Results
The demographics and baseline characteristics of the study population are shown in table 1.
Briefly, the majority of the study population was male (79%). The SA patients were more likely to have a medical history of hypertension compared with the ACS group (p=0.01).
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Levels of MP are higher in the CO than in the RA. Table 2 summarises the CO MP levels between the two patient groups. Total AnV+ MP were higher in the CO than RA in all patients. The ACS population had higher MPs when compared to those with SA (p=0.04). All MP sub-populations, endothelial, monocyte and platelet, were consistently higher in the ACS group (Figure 1 ). Blood from the RA also showed similar patterns ( Figure 2 ).
Levels of MPs reflect the clinical presentation
Total MPs from the CO were higher in the STEMI population compared with NSTEMI (p=0.02). PMP, EMP and NMP sub-populations were higher in the STEMI group compared to the NSTEMI and SA (Table 3) . TF+MMP levels did not differ between the STEMI and NSTEMI groups. TF+MMP were lower in the SA group compared with the STEMI and NSTEMI groups. Total AnV+MP and the other MP sub-populations (except from TF+MMP)
did not differ between the NSTEMI and SA groups. Similarly all MP were higher in the RA in the STEMI population compared with NSTEMI and SA patients (p=0.02) ( Table 4 ). There was no difference in TF+MMP levels between STEMI and NSTEMI. All MP were higher in the STEMI group compared with the NSTEMI group.
MP expression during ACS is time dependent
The median (IQR) ischemic times (defined as time from onset of symptoms to PCI, expressed in minutes) in the STEMI and NSTEMI groups were 285 (116-360) and 4320 (2100-6060) respectively (p<0.0001). Total and cell specific AnV+MPs, isolated from the CO of the NSTEMI group, were inversely correlated with ischaemic time (Figure 3) . Although there was a trend for negative correlation between the ischaemic time and all MP groups, the
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Platelet activation is a feature of ACS
Having observed elevated levels of platelet microparticles, (Figures 1-2) , further assessment of the role of platelets in ACS was undertaken. Levels of activated platelet MPs were measured in patients with ACS and SA. Figures 1 and 2 show that AnV+CD42a+CD62P+
PMP were much higher in the ACS group compared with the SA group in both the CO and RA (p=0.0008 and p=0.001 respectively). We have previously shown that activated platelets bind to leukocytes and can be detected as platelet monocyte aggregates (PMA) (30) . Levels of activated PMA were higher in the ACS group than in the SA group in both the CO (p=0.0003) and RA (p=0.04) Figure 5 . Soluble P-Selectin was also higher in the ACS group compared to the SA (Figure 4) , and did not differ between CO and RA.
Inflammatory indices are not good indicators of myocardial injury
There was a non-significant increase in levels of inflammatory markers in ACS patients as compared to those with SA (Table 5 ). Interestingly, with the exception of IL6, inflammatory indices were higher in the RA as compared to the CO. This contrasts with MPs, which were always higher in the CO. There was a broad correlation between levels of MPs, inflammatory indices and troponin T in ACS but not in SA. IL-6 in particular, correlated with levels of AnV+CD31+EMP (r=0.5; p=0.03) and AnV+TF+MMP (r=0.6; p=0.01). (Figure 5 )
Discussion
Our study has shown elevated levels of total MPs and MP subpopulations in CAD. Levels of MPs varied across the spectrum of CAD with STEMI cohort demonstrating higher levels
followed by NSTEMI and SA. Furthermore, levels were highest in the coronary artery, thus indicating culprit lesion as the possible source. Levels of MPs were better at identifying patients with severe ACS, than inflammatory markers taken from either the CO or RA.
Our results are in agreement with previous studies demonstrating elevated platelet and endothelial MPs in ACS (31) (32) (33) . We have also now demonstrated that the levels of leukocyte (neutrophil and monocyte) MPs are elevated in ACS.
We further noted negative correlation between the ischaemic time and total MP, PMP, EMP AnV+ MP release in the CO in the NSTEMI group but not in the STEMI group. This could be because the PPCI in the STEMI group occurred within hours after the onset of symptoms (compared to the PCI in the NSTEMI which occurred days after the onset of symptoms) which is probably the peak time of MP expression during ACS. This suggests that, in line with previous studies (20, 34) , there is a peak in MP release during the first 24-48 hours and thereafter MP levels fall (35) . Arguably, earlier sampling (on admission) of the NSTEMI patients would have yielded an expression of MP levels similar to that of the STEMI patients.
Our observation of high levels of AnV+CD62P+ MP in the CO raises the possibility that these could amplify vascular inflammation and thus contribute to lesion progression by further recruitment of inflammatory cells expressing P-selectin glycoprotein ligand (PSGL), which binds CD62P (P-selectin) (36,37). Since we also detected high CO AnV+CD62E+ MP, almost certainly derived from activated coronary endothelium, it is likely that E-selectin-PSGL binding could further mediate the interaction between inflammatory cells and activated endothelial cells and contribute to lesion progression (38) . In addition, the high coronary artery neutrophil derived microparticles we observed could further amplify vascular inflammation by binding to activated endothelium and resultant endothelial activation (39) .
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Further evidence of the importance of platelets in ACS came from our finding that patients with ACS had higher CD62P+PMA and soluble P-selectin compared to patients with SA, in both CO and the RA. The role of PMA formation in the pathophysiology of CHD remains unknown. Activated platelets express P-selectin on their surface, which mediates the plateletleukocyte interaction via the P-selectin-PSGL-1 bond leading to PMA formation with leukocyte activation, migration and recruitment at the site of inflammation (40, 41) . The platelet-monocyte interaction via the P-selectin-PSGL-1 pathway further increases the adhesive and pro-thrombotic properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins (42, 43) and by TF expression on the monocyte surface respectively (44, 45) . It has been shown that activated platelets lose their surface Pselectin despite the fact they continue to circulate and function (46) . Therefore PMA measurement may represent a more robust marker of platelet activation than detection of P- Variable EMP profile may indicate variable endothelial activation status (57). In addition, due to the small number of patients conclusions cannot be made and further studies needed.
Limitations of the study
Our study has a number of limitations. Firstly, the study sample was relatively small, making the interpretation of correlations less reliable in addition to statistical error (i.e. the observation that there was no statistical difference of the inflammatory markers expression between ACS and SA patients). Secondly, the effects of antiplatelet and anticoagulant therapy on MP production, even though standardised for all patient groups, and their prothrombotic activity (i.e. measuring TF activity which was not done in this study) was not fully analysed and needs further study. In addition sampling of the infarct related artery proximally to the culprit lesion or sampling of a bystander coronary artery could have strengthened our hypothesis that the culprit atheromatous coronary plaque is the predominant source of microparticle release. We also acknowledge the fact that our flow cytometry protocol is not according to international society of thrombosis and haemostasis recommended protcols.
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Conclusions
Future improvements in outcomes for patients with ACS will come from earlier recognition of the disease and a better understanding of its pathogenesis. While there has been considerable focus on the role of inflammation in ACS, we and others have failed to find that inflammatory markers alone identify patients with ACS as compared to SA. MPs appear to be a sensitive indicator of disease activity, both within the coronary artery and within the systemic circulation. This may reflect the local genesis of the MPs but may also indicate an important role for MPs in the pathogenic processes operating in ACS. Future studies should now address the potential for using MPs to characterise the nature and severity of ACS and explore the potential for modulating MP mediated pathogenic mechanisms to improve the outcome of patients with coronary vascular disease. A C C E P T E D M A N U S C R I P T Table 3 . Differences of microparticles expression (*10⁶/ml of plasma) in the three groups in the coronary artery (CO). MP levels expressed as medians with interquartile range (IQR). Table 4 . Differences of microparticles expression (*10⁶/ml of plasma) in the three groups in the right atrium (RA). MP levels expressed as medians with interquartile range (IQR). Table 5 . Differences of the inflammatory markers (medians (IQR)) between the acute coronary syndrome (ACS) and stable angina (SA) patients in the coronary (CO) and right atrium (RA). Statistical analysis performed using the Wilcoxon test. IL-6 (interleukin 6), SAA (serum amyloid A), TNF-α (tumour necrosis alpha) and hs-CRP (high sensitivity Creactive protein).
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